Is Wegovy approved for heart disease in the UK?

Yes. As of 23 July 2024, the MHRA approved Wegovy (semaglutide) to help prevent major cardiovascular events, such as heart attacks and strokes, in adults with established cardiovascular disease and a BMI of 27 or higher.

How much does Wegovy reduce the risk of heart attacks?

In a large international clinical trial involving over 17,600 adults, patients taking Wegovy experienced a 20% relative reduction in the risk of major cardiovascular events compared to those taking a placebo.

Does Wegovy treat heart disease directly?

No, Wegovy is not a direct cure or treatment for heart disease itself. It is a GLP-1 receptor agonist used for weight management that has been clinically proven to reduce the risk of secondary cardiovascular events when used alongside standard treatments.

Can you take Wegovy for heart health if you don't have diabetes?

Yes. The clinical trials demonstrating a 20% reduction in cardiovascular risk were specifically observed in patients without diabetes, showing the medication's cardiovascular benefits independent of blood sugar control.

UK Cardiology Update MHRA Guidance

Reviewed Last checked 3 Nov 2026

Clinical Overview

Wegovy and Heart Disease: What UK Patients Should Know

If you live in the UK and are managing your weight alongside your heart health, it helps to understand the link between Wegovy and heart disease. This guide explains how the medication works, the latest official MHRA approvals, and how it supports patients with existing cardiovascular conditions.

Medical Disclaimer: Wegovy does not treat heart disease directly, nor is it a cure. It is a prescription medicine that must be prescribed by a qualified healthcare provider alongside a reduced-calorie diet and increased physical activity. Speak to your doctor to determine if it is clinically appropriate for you.

What is the Link Between Wegovy and Heart Disease?

The term "cardiovascular disease" (CVD) includes a range of conditions that affect the heart or blood vessels, such as heart attacks and strokes. These conditions are often closely linked to obesity, poor diet, and other lifestyle factors.

Wegovy® (semaglutide) is a GLP-1 receptor agonist originally approved in the UK for weight loss. After new clinical evidence, it has been shown to reduce the risk of major cardiovascular events in people who already have established heart disease and a BMI of 27 kg/m² or higher.

Wegovy and Heart Disease: UK Approval & Clinical Evidence

Wegovy is the first weight-loss drug in the UK licensed specifically for the prevention of serious cardiovascular events in people living with cardiovascular disease and excess weight.

MHRA Approval (July 2024)

As of 23 July 2024, the UK's MHRA officially approved Wegovy to help prevent cardiovascular death, non-fatal heart attacks, and non-fatal strokes in specific at-risk patients.

The SELECT Clinical Trial

The approval was based on an international trial of over 17,600 adults with pre-existing cardiovascular disease. Participants were followed for an average of over three years.

20% Risk Reduction

In the trial, 6.5% of patients on Wegovy had a major cardiovascular event compared to 8% on a placebo. This represents a statistically significant 20% relative reduction in risk.

Independent of Diabetes

These results were seen in patients without diabetes. That gives a clear picture of Wegovy's effect on heart health, separate from blood sugar control.

How Wegovy Supports Cardiovascular Health

Semaglutide works by mimicking the GLP-1 hormone, which helps control appetite, blood sugar and digestion. Together, these effects support sustained weight loss, which eases pressure on the heart and blood vessels.

1. Appetite Control

It acts on the brain to help you feel full sooner and for longer, so you feel less hungry.

2. Digestion

It slows the emptying of the stomach, which contributes to prolonged satiety after meals.

3. Blood Sugar

It helps lower blood sugar levels after eating, improving overall metabolic function.

4. Administration

Taken as a once-weekly injection using a pre-filled pen, alongside a reduced-calorie diet and exercise.

Wegovy and Heart Disease: Safety Profile and Next Steps

Like all medications, Wegovy can cause side effects. The most common gastrointestinal side effects are usually mild and may improve over time as your body adjusts to the medication.

Nausea and vomiting
Diarrhoea
Constipation

Reporting Side Effects: If you experience any severe or persistent side effects, speak to your GP, pharmacist, or prescribing clinician immediately. In the UK, you can also report safety concerns directly through the official MHRA Yellow Card Scheme.

In Summary: Wegovy and Heart Disease

For people in the UK living with both excess weight and cardiovascular disease, Wegovy offers an evidence-based option to reduce the risk of serious heart events. It isn't a cure, but it can support long-term heart health when used alongside healthy lifestyle changes, ongoing medical support, and checking UK Wegovy pricing for long-term affordability.

Clinical infographic detailing the UK MHRA approval of Wegovy (semaglutide) for reducing cardiovascular risk in patients with established heart disease and a BMI over 27. — **Clinical Reference:** Wegovy (semaglutide) and UK cardiovascular risk reduction indications.

Sources referenced on this page

Linked from the text above:

MHRA officially approved www.gov.uk
MHRA Yellow Card Scheme yellowcard.mhra.gov.uk

Standing primary references for every iGovy page: